Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion - Yahoo Finance
Yahoo Finance · Nov 5, 1:30 PM
Microbot Medical® Strengthens IP Portfolio as it Continues - GlobeNewswire
GlobeNewswire · Nov 5, 1:30 PM
Microbot Medical is a commercial-stage medical device company selling LIBERTY, a single-use robotic system for peripheral endovascular procedures cleared by FDA in 2025.
Microbot's case rests on LIBERTY, a single-use robotic system for peripheral endovascular procedures, which began its full U.S. market release in April 2026 after FDA 510(k) clearance. In Q2 2026 revenue more than doubled from Q1 on repeat orders and new health systems, and Microbot expects CE Mark in Europe by the end of 2026. Microbot says its cash of about $67.4 million lasts more than twelve months from June 30.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: LIBERTY sales keep growing after launch
Does LIBERTY keep growing in revenue and accounts after the launch quarter?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Microbot's LIBERTY robot more than doubled revenue in Q2 after its full U.S. launch; CE Mark is expected by year-end
FDA-cleared robotic endovascular system posting triple-digit revenue growth — the bet is whether adoption scales before cash position forces a dilutive raise
LIBERTY cleared and commercially launched; whether rapid account growth translates to durable, scalable revenue before cash runs out is the question
LIBERTY's post-clearance commercial ramp tests whether robotic endovascular adoption can scale fast enough to sustain a small-cap medtech
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
vs. direct competitors
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.